Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OurofinoBSP:OFSA3 -2.19%68 EV-to-OCF is 8.82 as of Jul. 14, 2026, which is 61% below its 10-year median of 22.63. GuruFocus rates BSP:OFSA3 with a GF Score™ of 68/100 and a GF Value™ of R$26.86 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Ourofino ranks better than 55.06% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Ourofino's Enterprise Value is R$1,566 Mil.
Ourofino's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was R$178 Mil. Therefore, Ourofino's EV-to-OCF for today is 8.82.
The historical rank and industry rank for Ourofino's EV-to-OCF or its related term are showing as below:
BSP:OFSA3'
s EV-to-OCF Range Over the Past 10 Years
Min: 4.66 Med: 22.63 Max: 87.41
Current: 9
During the past 12 years, the highest EV-to-OCF of Ourofino was 87.41. The lowest was 4.66. And the median was 22.63.
BSP:OFSA3's EV-to-OCF is ranked better than 55.06% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.58
vs BSP:OFSA3: 9.00
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ourofino's share price for today is R$26.80.
Ourofino's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$4.494.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ourofino EV-to-OCF Related Terms
Ourofino EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Ourofino's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:OFSA3 vs ZTS, UTHR, VTRS: EV-to-OCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ourofino EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ourofino's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ourofino's EV-to-OCF falls into.
Ourofino's current Enterprise Value is R$1,566 Mil.
Ourofino's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$178 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ourofino (BSP:OFSA3) has a EV-to-OCF of 8.82 as of Jul. 14, 2026. This is 61% below median its historical median of 22.63. Over the past decade, Ourofino's EV-to-OCF has ranged from 4.66 to 87.41. According to the industry distribution chart, Ourofino ranks #453 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 44.9%.
Is Ourofino's EV-to-OCF too high?
Ourofino's current EV-to-OCF of 8.82 is 61% below median its 10-year median of 22.63. Over the past 10 years, this metric has ranged from a low of 4.66 to a high of 87.41. The Drug Manufacturers industry median EV-to-OCF is 10.58. Ourofino's value of 8.82 is 16.6% below this industry median. Based on the distribution chart, Ourofino ranks #453 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ourofino has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ourofino ranks #453 out of 1008 companies for EV-to-OCF. This puts Ourofino in the upper half of its industry. The industry median EV-to-OCF is 10.58. Ourofino's value of 8.82 is 16.6% below this benchmark. Historically, Ourofino's own EV-to-OCF has ranged from 4.66 to 87.41 over the past decade. While the company's 10-year median is 22.63 vs. the industry median of 10.58, Ourofino has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.58, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ourofino's current EV-to-OCF of 8.82 is 16.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ourofino's current EV-to-OCF is 8.82, which is 61% below median its own 10-year median of 22.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$26.86, compared to a current price of R$26.80 — trading 0.2% below its estimated fair value. The current EV-to-OCF is 8.82, which is 61% below median its 10-year median of 22.63 and 16.6% below the Drug Manufacturers industry median of 10.58. Ourofino's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current EV-to-OCF is 8.82 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ourofino (BSP:OFSA3) Overvalued in 2026?
Based on GuruFocus' analysis, Ourofino stock appears to be undervalued.
The current stock price of R$26.80 is trading 0.2% below its estimated GF Value™ of R$26.86.
GuruFocus considers Ourofino to be Fairly Valued.
Key valuation signals for BSP:OFSA3:
EV-to-OCF: 8.82 (61% below median its 10-year median of 22.63)
GF Value™: R$26.86 vs. price of R$26.80 (0.2% below fair value)
Industry Position: 16.6% below the Drug Manufacturers median (#453 of 1008)
No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
68GF Score
Get the complete analysis for BSP:OFSA3
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:OFSA3 has been successfully added to your 
